LinkedIn emplea cookies para mejorar la funcionalidad y el rendimiento de nuestro sitio web, así como para ofrecer publicidad relevante. Si continúas navegando por ese sitio web, aceptas el uso de cookies. Consulta nuestras Condiciones de uso y nuestra Política de privacidad para más información.
LinkedIn emplea cookies para mejorar la funcionalidad y el rendimiento de nuestro sitio web, así como para ofrecer publicidad relevante. Si continúas navegando por ese sitio web, aceptas el uso de cookies. Consulta nuestra Política de privacidad y nuestras Condiciones de uso para más información.
Company Profile Ranbaxy was incorporated in 1961 and went public in 1973. Ranbaxy Laboratories Limited (Ranbaxy), Indias largest pharmaceutical company. It is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company has a global footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. 5/8/2012 2
History When we set out on our way in 1961, little did we realize the impact we would make on the Indian and global pharmaceutical industry. Take a look at how Ranbaxy has grown through the decades...... History1961= Company incorporated1973= Ranbaxy goes public1977=Ranbaxy first joint venture in Lagos (Nigeria) is setup1983= A modern dosage forms facility at Dewas (MP) in India goes onStream.1990= Ranbaxy granted its first US Patent, for doxycline1994=Estabilished regional headquarters in UK and USA . Listed inLuxenburg stock exchange2000= forays in to Brazil, the largest pharmaceutical market in SouthAmerica.2005=Launches operations in Cannada.2011= Celebrates golden jubilee year 5/8/2012 3
Financials For the year 2011, the Company recorded Global Sales of US $ 2.1 Bn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 47% and 46% respectively. In 2011, North America,1. North America, the Companys largest market contributed sales of US $ 791 Mn,2. Europe contributing US $ 297 Mn3. Asia clocking sales of US $ 503 Mn. 5/8/2012 4
Mission/Values Ranbaxys mission is Enriching lives globally, with quality and affordable pharmaceuticals. Values1. Achieving customer satisfaction if fundamental to our business2. Provides products and services of the highest quality3. Ensure profitable growth and enhance wealth of the shareholders4. Fosters mutually beneficial relations with all our business partners5. Manage our operations with high concern for safety and environment.6. Be a responsible corporate citizen 5/8/2012 5
People The Companys business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by the passion of its over 14,000 strong multicultural workforce comprising of more than 50 nationalities, Ranbaxy continues to aggressively pursue its mission of Enriching lives globally, with quality and affordable pharmaceuticals. Top Management Dr Tsutomu Une Chairman Mr Arun Sawhney: CEO & Managing Director Independent Director1. Dr Anthony H Wild2. Mr Rajesh Shah3. Mr Akihiro Watanabe4. Mr Percy Shroff 5/8/2012 6
Products The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales. Ranbaxy robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedic s, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments. 5/8/2012 7
PRODUCTS OFFERED ANTI – INFECTION G.I & NUTRITIONALS CVS & DIABETES CNS NS AID & RELATED ANTI ALLERGANTS ANTI RETROVIRALS UROLOGY OTHERS
Recent Acquisitions &AlliancesTerapia (Romania) Zenotech (India)Be-Tabs (South Africa) Krebs (India)Allen (Italy) Jupiter Biosciences*(Ind.)Ethimed (Belgium) Cardinal Drugs (India)Mundogen (Spain) Auto-injector Tech.(USA) * Subject to due diligence
Business StrategyCurrent• Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes.Focus• Growth is well spread across geographies with focus on developed and emerging markets.Hybrid Model with Daiichi Sankyo• Endeavour to provide a wide basket of generic and innovator products, leveraging the unique Hybrid Business Model with Daiichi SankyoNew Areas• Focus in high growth potential segments like Vaccines and Biogenerics. (will add significant depth to the existing product pipeline.) 5/8/2012 11
R&D: Key Business strategy.R&D is a vital R&D History Daiichi Sankyocomponent of • Since 1970 Group.business strategy • first-of-its-kind world • Ranbaxys New Drug• sustainable class R&D centre Discovery Research was commissioned in (NDDR) was• long-term competitive 1994 transferred on July advantage • dedicated facilities for 2010• over 1,200 R&D personnel engaged generics research • Part of the strategy to and innovative strengthen the global in path-breaking research Research and research. Development • Headquartered in Gurgaon 5/8/2012 12
STRATEGIESRanbaxy is focused on increasing the momentum in the genericsbusiness in its key markets through organic and inorganic growthroutes. Growth is well spread across geographies with focus onemerging markets The Company continues to evaluate acquisitionopportunities in India, emerging and developed markets tostrengthen its business and competitiveness. Ranbaxy has forayedinto high growth potential segments like Biologics, Oncology andinjectables. These new growth areas will add significant depth to theexisting product pipeline.The Globalization Strategy Growth Strategy Poised For Growth API Development And Production Dosage Form Development And Manufacturing Contract Manufacturing
SWOT ANALYSIS:STRENGTHS: Presence in 23 of the 27 EU countries. Low cost of production. Efficient technologies for large number of Generics. Large pool of skilled technical manpower both in India and abroad. Increasing liberalization of government policies. Well developed industry with Strong manufacturing Base. Rich Bio-diversity. Non Infrenging products of Active Pharmaceuticals Ingredients. High standards of purity.
Opportunities: Growing incomes. Growing attention for health. New diagnoses and new social diseases. New therapy approaches. Spreading attitude for soft medication (OTC drugs) Spreading use of Generic Drugs. Globalization Easier international trading. New markets are opening. Supply of generis drugs to developed markets Contarct manufacturing arrangements with MNCs. Niche player of global Pharmaceuticals and R&D
WEAKNESS: Fragmentation of installed capacities. Low technology level of Capital Goods of this section. Non-availability of major intermediaries for bulk drugs. Lack of experience to exploit efficiently the new patent regime. Low share of India in World Pharmaceutical Production (1.2% of world production but having 16.1% of worlds population). Very low level of Biotechnology in India and also for New Drug Discovery Systems. Low level of strategic planning for future and also for technology forecasting. Production of spurious and low Quality drugs tarnishes the images of industry at home and abroad. Production of Duplicate drugs Absence of Association between Institutes and Industry..
THREATS: Competition From MNCs Containment of rising health-care cost. High Cost of discovering new products and fewer discoveries. Transformation of process patent to product patent. Stricter registration procedures. High entry cost in newer markets. High cost of sales and marketing. Non tarrif barriers imposed by developed countries. Competition, particularly from generic products. Switching over form process patent to product patent. Drug price control order put unrealistic ceilings on product prices and profitability and preventa company from generating investible surplus